554 related articles for article (PubMed ID: 11205904)
21. Lovastatin induces apoptosis in malignant mesothelioma cells.
Rubins JB; Greatens T; Kratzke RA; Tan AT; Polunovsky VA; Bitterman P
Am J Respir Crit Care Med; 1998 May; 157(5 Pt 1):1616-22. PubMed ID: 9603146
[TBL] [Abstract][Full Text] [Related]
22. Apomine enhances the antitumor effects of lovastatin on myeloma cells by down-regulating 3-hydroxy-3-methylglutaryl-coenzyme A reductase.
Roelofs AJ; Edwards CM; Russell RG; Ebetino FH; Rogers MJ; Hulley PA
J Pharmacol Exp Ther; 2007 Jul; 322(1):228-35. PubMed ID: 17412884
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of the class II HMG-CoA reductase of Pseudomonas mevalonii.
Hedl M; Rodwell VW
Protein Sci; 2004 Jun; 13(6):1693-7. PubMed ID: 15152097
[TBL] [Abstract][Full Text] [Related]
24. Clavaric acid and steroidal analogues as Ras- and FPP-directed inhibitors of human farnesyl-protein transferase.
Lingham RB; Silverman KC; Jayasuriya H; Kim BM; Amo SE; Wilson FR; Rew DJ; Schaber MD; Bergstrom JD; Koblan KS; Graham SL; Kohl NE; Gibbs JB; Singh SB
J Med Chem; 1998 Nov; 41(23):4492-501. PubMed ID: 9804689
[TBL] [Abstract][Full Text] [Related]
25. Lovastatin inhibits tumor growth and lung metastasis in mouse mammary carcinoma model: a p53-independent mitochondrial-mediated apoptotic mechanism.
Shibata MA; Ito Y; Morimoto J; Otsuki Y
Carcinogenesis; 2004 Oct; 25(10):1887-98. PubMed ID: 15180944
[TBL] [Abstract][Full Text] [Related]
26. The HMG-CoA reductase inhibitor lovastatin protects cells from the antineoplastic drugs doxorubicin and etoposide.
Bardeleben RV; Dunkern T; Kaina B; Fritz G
Int J Mol Med; 2002 Oct; 10(4):473-9. PubMed ID: 12239596
[TBL] [Abstract][Full Text] [Related]
27. Lovastatin suppresses invasiveness of anaplastic thyroid cancer cells by inhibiting Rho geranylgeranylation and RhoA/ROCK signaling.
Zhong WB; Liang YC; Wang CY; Chang TC; Lee WS
Endocr Relat Cancer; 2005 Sep; 12(3):615-29. PubMed ID: 16172195
[TBL] [Abstract][Full Text] [Related]
28. Requirement for mevalonate in the control of proliferation of human breast cancer cells.
Wejde J; Blegen H; Larsson O
Anticancer Res; 1992; 12(2):317-24. PubMed ID: 1580550
[TBL] [Abstract][Full Text] [Related]
29. Epidermal growth factor receptor-targeted therapy potentiates lovastatin-induced apoptosis in head and neck squamous cell carcinoma cells.
Mantha AJ; McFee KE; Niknejad N; Goss G; Lorimer IA; Dimitroulakos J
J Cancer Res Clin Oncol; 2003 Nov; 129(11):631-41. PubMed ID: 12942316
[TBL] [Abstract][Full Text] [Related]
30. Synergistic anti-tumor efficacy of lovastatin and protein kinase C-beta inhibitor in hepatocellular carcinoma.
Kim W; Yoon JH; Kim JR; Jang IJ; Bang YJ; Kim YJ; Lee HS
Cancer Chemother Pharmacol; 2009 Aug; 64(3):497-507. PubMed ID: 19096848
[TBL] [Abstract][Full Text] [Related]
31. Blocking protein geranylgeranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells.
Xia Z; Tan MM; Wong WW; Dimitroulakos J; Minden MD; Penn LZ
Leukemia; 2001 Sep; 15(9):1398-407. PubMed ID: 11516100
[TBL] [Abstract][Full Text] [Related]
32. Differentiation and apoptosis induction by lovastatin and γ-tocotrienol in HL-60 cells via Ras/ERK/NF-κB and Ras/Akt/NF-κB signaling dependent down-regulation of glyoxalase 1 and HMG-CoA reductase.
Chen CC; Liu TY; Huang SP; Ho CT; Huang TC
Cell Signal; 2015 Nov; 27(11):2182-90. PubMed ID: 26208883
[TBL] [Abstract][Full Text] [Related]
33. Proteomics to display lovastatin-induced protein and pathway regulation in rat liver.
Steiner S; Gatlin CL; Lennon JJ; McGrath AM; Aponte AM; Makusky AJ; Rohrs MC; Anderson NL
Electrophoresis; 2000 Jun; 21(11):2129-37. PubMed ID: 10892724
[TBL] [Abstract][Full Text] [Related]
34. HMG-CoA reductase inhibition reduces the proinflammatory activation of human vascular smooth muscle cells by the terminal complement factor C5b-9.
Viedt C; Shen W; Fei J; Kamimura M; Hänsch GM; Katus HA; Kreuzer J
Basic Res Cardiol; 2003 Nov; 98(6):353-61. PubMed ID: 14556080
[TBL] [Abstract][Full Text] [Related]
35. Cell-based screen of HMG-CoA reductase inhibitors and expression regulators using LC-MS.
Gerber R; Ryan JD; Clark DS
Anal Biochem; 2004 Jun; 329(1):28-34. PubMed ID: 15136164
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro.
Flint OP; Masters BA; Gregg RE; Durham SK
Toxicol Appl Pharmacol; 1997 Jul; 145(1):91-8. PubMed ID: 9221828
[TBL] [Abstract][Full Text] [Related]
37. The statins as anticancer agents.
Chan KK; Oza AM; Siu LL
Clin Cancer Res; 2003 Jan; 9(1):10-9. PubMed ID: 12538446
[TBL] [Abstract][Full Text] [Related]
38. The effect of statins in colorectal cancer is mediated through the bone morphogenetic protein pathway.
Kodach LL; Bleuming SA; Peppelenbosch MP; Hommes DW; van den Brink GR; Hardwick JC
Gastroenterology; 2007 Oct; 133(4):1272-81. PubMed ID: 17919499
[TBL] [Abstract][Full Text] [Related]
39. The length of 5'-untranslated leader sequences influences distribution of 3-hydroxy-3-methylglutaryl-coenzyme A reductase mRNA in polysomes: effects of lovastatin, oxysterols, and mevalonate.
Gayen AK; Peffley DM
Arch Biochem Biophys; 1995 Oct; 322(2):475-85. PubMed ID: 7574724
[TBL] [Abstract][Full Text] [Related]
40. Residual effects of lovastatin and simvastatin on urinary mevalonate excretions in patients with familial hypercholesterolemia.
Pappu AS; Bacon SP; Illingworth DR
J Lab Clin Med; 2003 Apr; 141(4):250-6. PubMed ID: 12677170
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
